GPC3特异性探针荧光成像在肝细胞癌中的应用研究

Objective To study the glypican 3 (GPC3) fluorescent probe imagings in hepatocellular carcinoma (HCC) tissues and to determine its prognostic value in HCC patients. Methods The data of 87 patients who were treated at the Affiliated Hospital of Southwest Medical University from January 2019 to August 2020 were retrospectively analyzed. There were 75 males and 12 females, with the age of (56. 1 ± 11.9) years. The expressions of GPC3 were measured by immunohistochemistry and by the fluorescent probe. The results obtained by these two tests were compared. Patients were followed up for recurrence after hepatectomy. Univariate and multivariate Cox regression analyses were used to analyze factors influencing recurrence-free survival. Results Detection of the GPC3 expression by GPC3 fluorescence probe was consistent with the results obtained by immunohistochemical studies (Kappa = 0. 84, P < 0. 001). The positive rates of GPC3 fluorescent probe was 79. 3% (69/87), compared with 80. 4% (70/87) by immunohistochemistry studies, with no significant difference between the two groups (P > 0. 05). The patients were then divided into the low differentiation group (n = 30) and the middle high differentiation group (n = 57) by the degrees of tumor differentiation. The fluorescence intensity in the low differentiation group was 134. 4 (128. 0, 144. 7) a. u. which was significantly different from the middle high differentiation group of 84. 8 (0, 108. 5) a. u. (Z = - 7. 52, P < 0. 001). The median fluorescence ntensity of 87 patients with HCC was 108.6 a. u.. Multivariate Cox regression analysis showed that patients with a GPC3 fluorescence intensity ≥108. 6 a. u. (HR =2.01, 95% CI; 1. 21 -3. 53, P =0. 008) had a significant increased risk of recurrence after hepatectomy. Conclusion The expressions of GPC3 in HCC were consistent between the studies by using either a GPC3 specific fluorescent probe or immunohistochemistry studies. A GPC3 fluorescence ntensity ≥108. 6 a. u. was a risk factor of recurrence after hepatectomy in patients with HCC.